It was intriguing that myelin-specific T cells from MS patients with benign disease had a significantly augmented galectin-9–TIM-3 cell death pathway compared to MS patients with active disease (Saresella et al., ECTRIMS 2011, Abstract P324). This evidence concerns the gene HAVCR2 and myeloid sarcoma.